The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Open accessAbstract
In an attempt to treat cancer patients with ERBB2 overexpressing tumors, we developed a chimeric antigen receptor (CAR) based on the widely used humanized monoclonal antibody (mAb) Trastuzumab (Herceptin). An optimized CAR vector containing CD28, 4-1BB, and CD3zeta signaling moieties was assembled in a gamma-retroviral vector and used to transduce autologous peripheral blood lymphocytes (PBLs) from a patient with colon cancer metastatic to the lungs and liver, refractory to multiple standard treatments. The gene transfer efficiency into autologous T cells was 79% CAR(+) in CD3(+) cells and these cells demonstrated high-specific reactivity in in vitro coculture assays. Following completion of nonmyeloablative conditioning, the patient received 10(10) cells intravenously. Within 15 minutes after cell infusion the patient experienced respiratory distress, and displayed a dramatic pulmonary infiltrate on chest X-ray. She was intubated and despite intensive medical intervention the patient died 5 days after treatment. Serum samples after cell infusion showed marked increases in interferon-gamma (IFN-gamma), granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-10, consistent with a cytokine storm. We speculate that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citationTrastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationJohnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Self-citationDudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Self-citationA Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Till, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Systemic inflammation after trauma
Lenz, A., Franklin, G. A., & Cheadle, W. G. (2007) · Injury · doi:10.1016/j.injury.2007.10.003 · Cited by 600
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Rubin, I., & Yarden, Y. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s3 · Cited by 500
Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 423
Wang, H., & Ma, S. (2008) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2007.10.031 · Cited by 408
Fisher, B., Packard, B. S., Read, E. J., Carrasquillo, J. A., Carter, C. S., Topalian, S. L., Yang, J. C., Yolles, P., Larson, S. M., & Rosenberg, S. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.2.250 · Cited by 328
Self-citationCHATENOUD, L., FERRAN, C., LEGENDRE, C., THOUARD, I., MERITE, S., REUTER, A., GEVAERT, Y., KREIS, H., FRANCHIMONT, P., & BACH, J.-F. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 320
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
Wang, C., Lin, G. H. Y., McPherson, A. J., & Watts, T. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00765.x · Cited by 298
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Self-citationStanilova, S. A., Miteva, L. D., Karakolev, Z. T., & Stefanov, C. S. (2006) · Intensive Care Medicine · doi:10.1007/s00134-005-0022-4 · Cited by 244
The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract
Ross, J. S., & McKenna, B. J. (2001) · Cancer Investigation · doi:10.1081/cnv-100103852 · Cited by 243
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 240
Peoples, G. E., Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., & Ponniah, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.047 · Cited by 216
SnapShot: EGFR Signaling Pathway
Yarden, Y., & Shilo, B.-Z. (2007) · Cell · doi:10.1016/j.cell.2007.11.013 · Cited by 199
Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., Ponniah, S., & Peoples, G. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2575 · Cited by 183
Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review
Sgro, C. (1995) · Toxicology · doi:10.1016/0300-483x(95)03123-w · Cited by 170
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Beano, A., Signorino, E., Evangelista, A., Brusa, D., Mistrangelo, M., Polimeni, M. A., Spadi, R., Donadio, M., Ciuffreda, L., & Matera, L. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-25 · Cited by 161
Taraban, V. Y., Rowley, T. F., O'Brien, L., Chan, H. T. C., Haswell, L. E., Green, M. H. A., Tutt, A. L., Glennie, M. J., & Al‐Shamkhani, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200212)32:12<3617::aid-immu3617>3.0.co;2-m · Cited by 150
Lassus, H. J., Sihto, H. J., Leminen, A., Joensuu, H., Isola, J. J., Nupponen, N. N., & Bützow, R. C. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0054-4 · Cited by 146
Bernhard, H., Neudorfer, J., Gebhard, K., Conrad, H., Hermann, C., Nährig, J., Fend, F., Weber, W., Busch, D. H., & Peschel, C. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0355-7 · Cited by 146
Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner, L. M., Clark, J. I., Davey, M., Li, W. S., de Palazzo, I. G., Ring, D. B., & Alpaugh, R. K. (1995) · PubMed · Cited by 139
Cohen, C. J., Zheng, Z., Bray, R. B., Zhao, Y., Sherman, L. A., Rosenberg, S. A., & Morgan, R. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5799 · Cited by 125
Self-citationThe T-Body Approach: Redirecting T Cells with Antibody Specificity
Eshhar, Z. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_14 · Cited by 111
Parihar, R., Nadella, P. C., Lewis, A., Jensen, R. R., Hoff, C. D., Dierksheide, J. E., VanBuskirk, A. M., MAGRO, C. M. J., Young, D. C., Shapiro, C. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0265 · Cited by 111
Gene modification strategies to induce tumor immunity.
Murphy, A., Westwood, J. A., Teng, M., Moeller, M., Darcy, P., & Kershaw, M. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.007 · Cited by 70
Safety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Mani, A., Roda, J. M., Young, D. C., Caligiuri, M. A., Fleming, G. F., Kaufman, P. A., Brufsky, A., Ottman, S., Carson, W. E., & Shapiro, C. L. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0251-7 · Cited by 46
Theoret, M. R., Cohen, C. J., Nahvi, A. V., Ngo, L. T., Suri, K. B., Powell, D. J., Dudley, M. E., Morgan, R. A., & Rosenberg, S. A. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.083 · Cited by 45
Self-citationMorse, M. A., Hobeika, A. C., Osada, T., Niedzwiecki, D., Marcom, P. K., Blackwell, K., Anders, C. K., Devi, G. R., Lyerly, H. K., & Clay, T. M. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-42 · Cited by 45
Tischendorf, J. J. W., Yagmur, E., Scholten, D., Vidacek, D., Koch, A. H., Winograd, R., Gressner, A., Trautwein, C., Wasmuth, H., & Lammert, F. (2007) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2007.00712.x · Cited by 41
The role of cytokine polymorphisms in rejection after solid organ transplantation
Marshall, S. E., & Welsh, K. (2001) · Genes and Immunity · doi:10.1038/sj.gene.6363795 · Cited by 33
Lotem, M., Zhao, Y., Riley, J. P., Hwu, P., Morgan, R. A., Rosenberg, S. A., & Parkhurst, M. R. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211312.36363.56 · Cited by 28
Self-citationImmunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Vera, J. F., Brenner, M. K., & Dotti, G. (2009) · Current Gene Therapy · doi:10.2174/156652309789753338 · Cited by 25
Girnita, D. M., Webber, S. A., & Zeevi, A. (2008) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2008.08.002 · Cited by 22
Scheving, L. A., Zhang, L., Stevenson, M., Kwak, E. S., & Russell, W. E. (2006) · American Journal of Physiology - Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00328.2005 · Cited by 20
Cited by
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Metadata
- Authors
- Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 18
- Issue
- 4
- Pages
- 843-851
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2094945699
- Cited by
- 2,533
- References
- 60
- FWCI
- 35.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.